Last checked at 6 Aug 2021 12:07
LONDON MARKET MIDDAY: Caution dominates ahead of US nonfarm payrolls
LONDON MARKET MIDDAY: Caution dominates ahead of US nonfarm payrolls
Read more
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Hikma Pharmaceuticals Share News (HIK)
HIK Share
Price
HIK Share
News
HIK Share
Chat
HIK Share
Trades834
HIK
Live RNS
HIK Share
Charts
HIK Level 2
Console
HIK Live
Share Price
HIK Broker
Ratings
HIK Directors
Deals
HIK Financial
Diary
HIK
Fundamentals
HIK Short
Positions
HIK
Media
Hikma Pharmaceuticals Information
Share Price Information for Hikma Pharmaceuticals (HIK)
Share Price is delayed by 15 minutes
Get Live Data
Share Price:
1,939.00
Bid:
1,937.00
Ask:
1,938.00
Change:
7.00 (0.36%)
Spread:
1.00 (0.052%)
Open:
1,926.00
High:
1,948.00
Low:
1,904.00
Prev. Close:
1,932.00
Last checked at -
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.MARKET TALK: UBS Raises Hikma Price Target
Wed, 23rd Jun 2010 09:16
0816 GMT [Dow Jones] UBS raises Hikma Pharmaceuticals (HIK.LN) price target to 770p from 715p to adjust for current FX rates and a slightly higher interest charge than previously anticipated. Notes Hikma has launched oncology injectable products in the Middle East and North Africa, and says this is a significant opportunity, given lower Injectable generic penetration. Adds the company continues to roll out Injectables in Europe, where the underlying business remains stable. Keeps the stock at buy. Shares +0.1% at 692p. (michele.maatouk@dowjones.com) Contact us in London. +44-20-7842-9464 Markettalk.eu@dowjones.com (END) Dow Jones Newswires June 23, 2010 04:16 ET (08:16 GMT)
More News
6 Aug 2021 09:03
LONDON MARKET OPEN: Stocks soft, dollar up as US nonfarm payrolls near
LONDON MARKET OPEN: Stocks soft, dollar up as US nonfarm payrolls near
Read more6 Aug 2021 08:40
TOP NEWS: Hikma hikes Generics guidance as interim profit swells
TOP NEWS: Hikma hikes Generics guidance as interim profit swells
Read more6 Aug 2021 07:42
LONDON MARKET PRE-OPEN: LSEG raises Refinitiv cost synergy guidance
LONDON MARKET PRE-OPEN: LSEG raises Refinitiv cost synergy guidance
Read more6 Aug 2021 07:22
Hikma lifts FY generics guidance as first-half profits, revenue jump
(Sharecast News) - Hikma Pharmaceuticals upgraded full-year guidance for its generics arm and reported a rise in first-half profit and revenue as it hailed a strong performance in both the generics and branded segments, and resilience in the injectables business.
Read more30 Jul 2021 16:05
UK earnings, trading statements calendar - next 7 days
UK earnings, trading statements calendar - next 7 days
Read more14 Jul 2021 19:38
IN BRIEF: Arecor ends first half of 2021 with solid cash position
IN BRIEF: Arecor ends first half of 2021 with solid cash position
Read more13 Jul 2021 10:00
BROKER RATINGS: Barclays upgrades Shell and EnQuest to Overweight
BROKER RATINGS: Barclays upgrades Shell and EnQuest to Overweight
Read more1 Jul 2021 09:51
BROKER RATINGS: Credit Suisse upgrades Legal & General and StanChart
BROKER RATINGS: Credit Suisse upgrades Legal & General and StanChart
Read more21 Jun 2021 14:51
UPDATE 1-U.S. Supreme Court denies Amarin's bid to revive Vascepa drug patents
(Adds background to case, paragraphs 4-10)By Blake BrittainWASHINGTON, June 21 (Reuters) - The U.S. Supreme Court on Monday rejected a bid by an Amarin Corp PLC subsidiary to revive patents on its heart drug Vascepa in a legal battle against gener...
Read more21 Jun 2021 14:31
U.S. Supreme Court denies Amarin's bid to revive Vascepa drug patents
WASHINGTON, June 21 (Reuters) - The U.S. Supreme Court on Monday rejected a bid by an Amarin Corp PLC subsidiary to revive patents on its heart drug Vascepa in a legal battle against generic drugmakers Hikma Pharmaceuticals PLC and Dr. Reddy's La...
Read more8 Jun 2021 13:54
Tuesday broker round-up
(Sharecast News) - tinyBuild: Berenberg reiterates buy with a target price of 295p.
Read more6 May 2021 09:46
BROKER RATINGS: Exane BNP downgrades three property companies
BROKER RATINGS: Exane BNP downgrades three property companies
Read more30 Apr 2021 17:01
LONDON MARKET CLOSE: Stocks close out impressive April to end higher
LONDON MARKET CLOSE: Stocks close out impressive April to end higher
Read more30 Apr 2021 08:58
TOP NEWS: Hikma Pharma confident after promising start to year
TOP NEWS: Hikma Pharma confident after promising start to year
Read more